SynergenX Health review

SynergenX is a hormone clinic chain with 64 physical locations across ten states that also runs telehealth, rather than a storefront that ships vials. Its site names two peptides outright, Sermorelin Peptide Therapy and a PT-141 peptide. Two things limit who it is for. It publishes no price for either peptide — its $150 figure belongs to compounded semaglutide and is not a peptide price — and its telehealth program is currently open to Texas patients only. Everyone else is being invited into a room.

SynergenX Health is a hormone and weight-loss clinic chain operating 64 locations across Texas, Illinois, Tennessee, Colorado, Arkansas, Indiana, Missouri, North Carolina, Ohio and Oklahoma, formed through a merged network with Low T Center. Its core business is hormone optimization, including testosterone replacement therapy, with a telehealth GLP-1 weight-loss program built on compounded semaglutide alongside it. Its site names Sermorelin Peptide Therapy in its service navigation and a PT-141 peptide under its women's services, and offers comprehensive hormone testing with an out-of-pocket option for new patients.

Hybrid, and weighted heavily toward in-person care. The clinic network is the substance of the business — 64 locations means a physical bench, real appointment slots and a hormone practice that predates the telehealth boom, which is a different risk profile from a platform founded last year. Its telehealth arm, though, is narrow: the online sign-up currently offers Texas as the only state, with more described as rolling out and no timeline published. For a national audience that makes this primarily a directory entry rather than a service you can start today. The GLP-1 program, which is the part of the site with published detail, runs on a $100 initial telehealth visit and $40 follow-ups every one to three months, with medication and refrigerated shipping stated as covered. What is not published anywhere is the peptide side of the operation: no price for sermorelin or PT-141, no dosing, no protocol detail, and no statement of whether labs are involved. Nor does the site name a compounding pharmacy, an accreditation, or a medical director, which for a chain of this size is a surprising omission rather than a typical one.

Absent for sermorelin and PT-141. Sermorelin Peptide Therapy and the PT-141 peptide are both named as services and neither carries a published figure anywhere on the site. The number the site does publish — compounded semaglutide starting as low as $150 for one month of treatment, with a $100 initial telehealth visit and $40 follow-ups — is a GLP-1 price, and it tells you nothing about what a peptide costs here. Two things to ask if you call: what a sermorelin protocol costs at your nearest clinic, since a chain with 64 locations may not price identically across ten states, and whether hormone lab work is billed separately from the therapy. Its published hormone testing offer — an insurance copay or $99 out of pocket for new patients — suggests labs are a separate line item rather than a bundled one.

Compounded where compounded, and not FDA-approved. Prescription required only if a licensed provider finds it appropriate. No compounding pharmacy is named, no accreditation is displayed and no medical director is published, so the supply chain behind an injectable here is less traceable than the clinic network in front of it. Compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, the two named peptides are quite different propositions. Sermorelin is a GHRH analog that stimulates your own pituitary rather than supplying growth hormone from outside, preserving a feedback loop that exogenous growth hormone overrides — a real, well-characterized mechanism whose long-term human outcome data stays thin past short-term IGF-1 movement. PT-141, bremelanotide, is the more interesting case: it is an FDA-approved drug, but for one narrow indication only, generalized hypoactive sexual desire disorder in premenopausal women, so a compounded version prescribed outside that population is off-label use of an approved molecule rather than an unapproved compound. Its testosterone line has a large randomized safety base and requires ongoing hematocrit, PSA and testosterone monitoring, which a clinic-based practice is structurally better placed to deliver than a shipping service. Individual results vary.